Senores Pharmaceuticals Share Price Target Senores Pharmaceuticals Ltd is a growing pharmaceutical company based in Ahmedabad, India, that specializes in the production and development of a wide range of medicines. The company has expanded its operations across key international markets such as the United States, Canada, and the United Kingdom, providing a variety of prescription drugs and over-the-counter products. Senores Pharmaceuticals is dedicated to not only manufacturing existing drugs but also enhancing them or developing new therapies to meet evolving medical needs.
Senores Pharmaceuticals Ltd is offering shares through an IPO (Initial Public Offering) that took place from December 20, 2024, to December 24, 2024. Here are the details:
Details
Information
IPO Date
December 20, 2024 – December 24, 2024
Listing Date
To Be Announced
Face Value
₹10 per share
Price Band
₹372 – ₹391 per share
Minimum Investment
₹14,136
Lot Size
38 shares
Total Issue Size
1,48,87,723 shares
Fresh Issue
1,27,87,723 shares
Offer for Sale
21,00,000 shares
Issue Type
Book Built Issue IPO
Listing At
BSE, NSE
Pre-issue Shareholding
3,32,65,865 shares
Post-issue Shareholding
4,60,53,588 shares
Senores Pharmaceuticals Business Model
Senores Pharmaceuticals is a major player in the pharmaceutical industry, focusing on producing complex and specialty medicines. The company has achieved substantial growth, particularly in key regulated markets such as the US, Canada, and the UK. With three R&D centers and an efficient manufacturing process, Senores continues to offer critical care injectables and active pharmaceutical ingredients (APIs) while working in over 43 emerging markets.
Senores Share Price Target for 2025
Price Range for 2025: ₹408 – ₹540
In 2025, Senores Pharmaceuticals is expect to continue its upward trajectory, with its stock price forecasted to range from ₹408 to ₹540. The company’s focus on high-demand, specialized drugs in various therapeutic categories, including antifungals and antibiotics, should help sustain its growth. With established markets in the US, Canada, and India, as well as strategic marketing agreements with global pharmaceutical players, Senores is poised for success in 2025.
Month
Minimum Price (Rs)
Maximum Price (Rs)
January
₹408
₹422
February
₹415
₹428
March
₹421
₹432
April
₹426
₹445
May
₹431
₹456
June
₹443
₹465
July
₹458
₹478
August
₹462
₹489
September
₹485
₹508
October
₹501
₹519
November
₹514
₹533
December
₹531
₹540
Senores Share Price Target for 2026
Price Range for 2026: ₹531 – ₹680
Senores Pharmaceuticals’ stock price is project to increase further in 2026. The company’s ongoing expansion in international markets, along with continued research and development of critical care injectables and active pharmaceutical ingredients, is expect to drive growth. The 2026 target range is ₹531 to ₹680, as Senores’ business continues to scale and mature.
Looking toward 2030, Senores Pharmaceuticals is anticipated to continue growing, with its stock price expect to range between ₹1050 and ₹1226. The company’s focus on R&D and developing complex molecules for underpenetrated markets is expect to solidify its position as an industry leader. In addition, the company’s extensive partnerships with both global and Indian pharmaceutical companies provide further opportunities for growth.
Month
Minimum Price (Rs)
Maximum Price (Rs)
January
₹1050
₹1069
February
₹1063
₹1088
March
₹1073
₹1098
April
₹1090
₹1123
May
₹1018
₹1130
June
₹1123
₹1138
July
₹1130
₹1147
August
₹1139
₹1168
September
₹1156
₹1179
October
₹1163
₹1190
November
₹1185
₹1213
December
₹1208
₹1226
Senores Share Price Target for 2040
Price Range for 2040: ₹2011 – ₹2431
In the long term, Senores Pharmaceuticals’ stock price could reach as high as ₹2431 by 2040. The company’s expertise in critical care injectables and active pharmaceutical ingredients positions it as an essential supplier in global healthcare. The growing demand for high-quality medicines, coupled with its strong R&D efforts, will likely drive continued stock price appreciation over the next decade.
Month
Minimum Price (Rs)
Maximum Price (Rs)
January
₹2011
₹2043
February
₹2030
₹2067
March
₹2051
₹2078
April
₹2065
₹2096
May
₹2073
₹2123
June
₹2102
₹2156
July
₹2141
₹2186
August
₹2167
₹2215
September
₹2200
₹2267
October
₹2248
₹2328
November
₹2293
₹2388
December
₹2367
₹2431
Senores Share Price Target for 2050
Price Range for 2050: ₹4667 – ₹5244
Looking to 2050, Senores Pharmaceuticals is expect to see continued growth due to its strong foundations in R&D and strategic business relationships. The company’s efficient manufacturing and development processes, paired with its long-term partnerships, will likely lead to even higher stock prices in the future. The estimate price range for 2050 is ₹4667 to ₹5244.
Month
Minimum Price (Rs)
Maximum Price (Rs)
January
₹4667
₹4690
February
₹4683
₹4756
March
₹4740
₹4834
April
₹4790
₹4856
May
₹4811
₹4878
June
₹4835
₹4936
July
₹4890
₹5047
August
₹4968
₹5073
September
₹5028
₹5123
October
₹5076
₹5158
November
₹5132
₹5218
December
₹5190
₹5244
Senores Pharmaceuticals Financial Performance
The company’s financial results from March 2022 to March 2025 indicate impressive growth across various key metrics:
Year
Mar 2022
Mar 2023
Mar 2024
Sales (Cr)
14
35
215
Expenses (Cr)
12
23
173
Operating Profit (Cr)
2
13
42
OPM %
14%
36%
19%
Other Income (Cr)
0
4
3
Interest (Cr)
1
2
9
Depreciation (Cr)
1
2
10
Profit Before Tax (Cr)
1
12
25
Net Profit (Cr)
1
8
33
EPS (₹)
Bull Case vs Bear Case
Bull Case
Strong market presence in regulated and emerging markets.
Focus on complex and underpenetrated medicines.
Long-term partnerships with global pharmaceutical companies.
Revenue diversification through licensing and CDMO services.
Bear Case
Delays in the highly regulated markets could affect growth.
Intense competition in the pharmaceutical industry.
High debtor days of 191, potentially affecting cash flow.
Who is the owner of Senores Pharmaceuticals?
Swapnil Jatinbhai Shah is the promoter and managing director of Senores Pharmaceuticals. He has more than 15 years of experience in the pharmaceutical industry.
Is Senores Pharmaceuticals IPO good?
Senores Pharmaceuticals’ shares debuted with over a 50% premium on Indian exchanges, reflecting a robust investor response to the IPO, which was subscribed over 93 times. The company focuses on pharmaceutical products for regulated markets and has strong revenue and profit growth in FY24.
Is it good to invest in Senores Pharmaceuticals?
The Captial Market (CapitalMarket.com) rating for Senores Pharmaceuticals IPO is 42. Their analysis recommends Avoid, However active risk seekers can try for the IPO.
Disclaimer
DISCLAIMER
Browvopetshop.com is not liable for any claims, losses, or damages from the information provided. Content is general and not financial advice—consult a professional before investing. Personal financial factors are not considered, and potential conflicts of interest may exist. Trademarks, logos, and company names belong to their respective owners.
